Xphozah 10 Mg Tablet, Film Coated
NDC Package 73154-110-99

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Xphozah 10 Mg (tenapanor) tablets is xPHOZAH is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. This formulation utilizes a tablet, film coated delivery system. Marketed by Ardelyx, Inc., this product is identified by NDC 73154-110 and is authorized under FDA application NDA213931.

Identification & Billing

NDC Package Code
73154-110-99
Package Description
14 TABLET, FILM COATED in 1 BOTTLE
Product Code
73154-110
11-Digit Billing Format
73154011099
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Xphozah 10 Mg
Non-Proprietary Name
Tenapanor
Substance Name
Tenapanor Hydrochloride
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
TENAPANOR HYDROCHLORIDE 10 mg/1
Pharmacologic Class
Usage Information
XPHOZAH is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Regulatory & Marketing

Labeler Name
Ardelyx, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA213931
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
10-17-2023
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
Yes

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (73154-110). Click a package code to view its specific billing and regulatory data.

73154-110-14
14 TABLET, FILM COATED in 1 BOTTLE
73154-110-60
60 TABLET, FILM COATED in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 73154-110-99 identifies a specific commercial package of 14 tablet, film coated in 1 bottle of Xphozah 10 Mg, a human prescription drug labeled by Ardelyx, Inc.. This tablet, film coated is formulated for oral use and contains tenapanor hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Ardelyx, Inc. on October 17, 2023. The current certification is valid through December 31, 2026.

How is this Ardelyx, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 73154011099. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
73154-110-99
11-Digit CMS (5-4-2)
73154-0110-99

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.